| pubmed-article:7090421 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7090421 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:7090421 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:7090421 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:7090421 | lifeskim:mentions | umls-concept:C0032821 | lld:lifeskim |
| pubmed-article:7090421 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
| pubmed-article:7090421 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7090421 | pubmed:dateCreated | 1982-8-7 | lld:pubmed |
| pubmed-article:7090421 | pubmed:abstractText | 1. The metabolism of potassium [2-14C]octan-2-sulphate and potassium octan-2-[35S]sulphate was investigated in the rat. Following oral administration, the bulk of the radioactivity was eliminated in the urine within 24 h. 2. Whole-body radioautography showed the liver to be the principal site of tissue accumulation of radiolabel following administration of 14C- or 35S-labelled DL-octan-2-sulphate. 3. Octan-2-sulphate was extensively degraded in vivo. The major urinary components are five sulphate estes, present in urine in essentially the same proportions regardless of label. The relative proportions of radioactivity associated with the urinary components showed considerable differences between male and female rats. 4. Three of the components have been identified as butanoate-3-sulphate, hexanoate-5-sulphate and octanoate-7-sulphate. The remaining metabolite was tentatively identified as an aldehyde derivative of octan-2-sulphate, a possible intermediate in the formation of octanoate-7-sulphate. | lld:pubmed |
| pubmed-article:7090421 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7090421 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7090421 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7090421 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7090421 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7090421 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7090421 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7090421 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:7090421 | pubmed:issn | 0049-8254 | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:DodgsonK SKS | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:OlavesenA HAH | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:HowesDD | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:PowellG MGM | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:BlackJ GJG | lld:pubmed |
| pubmed-article:7090421 | pubmed:author | pubmed-author:MaggsJ LJL | lld:pubmed |
| pubmed-article:7090421 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7090421 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:7090421 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7090421 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7090421 | pubmed:pagination | 101-9 | lld:pubmed |
| pubmed-article:7090421 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:meshHeading | pubmed-meshheading:7090421-... | lld:pubmed |
| pubmed-article:7090421 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:7090421 | pubmed:articleTitle | Metabolism in the rat of potassium DL-octan-2-sulphate, a secondary alkyl sulphate. | lld:pubmed |
| pubmed-article:7090421 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7090421 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
